Russian Journal of Child NeurologyRussian Journal of Child NeurologyРусский журнал детской неврологии2073-88032412-9178Publishing House ABV Press12010.17650/2073-8803-2015-10-4-47-54CLINICAL OBSERVATIONSКЛИНИЧЕСКИЕ НАБЛЮДЕНИЯRUFINAMIDE (INOVELON) IN THE TREATMENT OF LENNOX–GASTAUT SYNDROME (A REVIEW OF LITERATURE AND CLINICAL CASE)Руфинамид (Иновелон) в лечении синдрома Леннокса–Гасто (обзор литературы и описание случая)MukhinK. Yu.МухинК. Ю.
Russian Federation

6 Svetlaya St., Puchkovo Village, Pervomayskoe Settlement, Moscow, 143396

143396, Москва, пос. Первомайское, дер. Пучково, ул. Светлая, 6

center@epileptologist.ruPylaevaO. A.ПылаеваО. А.
Russian Federation

6 Svetlaya St., Puchkovo Village, Pervomayskoe Settlement, Moscow, 143396

143396, Москва, пос. Первомайское, дер. Пучково, ул. Светлая, 6

Svt. Luka’s Institute of Child Neurology and EpilepsyООО «Институт детской неврологии и эпилепсии им. Святителя Луки»1512201510447541601201616012016Copyright ©; 2015, ABV-PressCopyright ©; 2015, АБВ-пресс2015ABV-PressАБВ-прессhttps://rjdn.abvpress.ru/jour/about/editorialPolicieshttps://rjdn.abvpress.ru/jour/article/view/120

Lennox–Gastaut syndrome (LGS) is childhood-onset epileptic encephalopathy manifested by frequent polymorphic seizures, including tonic axial, obvious cognitive impairments, characteristic ECG changes, and therapeutic resistance. Due to the concurrence of several types of seizures in the clinical presentation of the disease and their resistance to drug therapy, great hopes are pinned on the design of novel antiepileptic drugs with fundamentally other mechanisms of action and aimed specially at treating this severe type of epilepsy. The authors review the foreign literature on the new antiepileptic drug rufinamide (Inovelon) registered in Russia in January 2015 to directly treat LGS as adjunctive treatment in children 4 years and older and adults. Multiple trials have demonstrated that rufinamide has efficacy and good tolerability in treating LGS.

The authors describe an observed case of the efficacy of rufinamide in a 17-year-old male patient with LGS. Despite the drug resistance of epilepsy and no response to multiple antiepileptic drugs used alone and in different combinations, the incorporation of rufinamide into a treatment regimen had a pronounced therapeutic effect: the frequency of convulsive seizures decreased by 70 %. At the time of writing this paper, the patient has been receiving rufinamide for more 5 months. He has been tolerating the therapy well.

epilepsydrug-resistant types of epilepsyLennox–Gastaut syndromeepileptic seizuretonic epileptic seizureantiepileptic drugrufinamidemechanism of actionpharmacokineticsefficacytolerabilityэпилепсиярезистентные формы эпилепсиисиндром Леннокса–Гастоэпилептический приступтонический эпилептический приступантиэпилептический препаратруфинамидмеханизм действияфармакокинетикаэффективностьпереносимость1. Бадалян Л.О., Темин П.А., Никанорова М.Ю., Мухин К.Ю. Синдром Леннокса–Гасто. Журнал неврологии и психиатрии им. С.С. Корсакова 1993;93(2):96–9. [Badalyan L.О., Теmin P.А., Nikanorova М.Yu., Мukhin K.Yu. Lennox–Gastaut syndrome. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 1993;93(2):96–9. (In Russ.)].Бадалян Л.О., Темин П.А., Никанорова М.Ю., Мухин К.Ю. Синдром Леннокса–Гасто. Журнал неврологии и психиатрии им. С.С. Корсакова 1993;93(2):96–9. [Badalyan L.О., Теmin P.А., Nikanorova М.Yu., Мukhin K.Yu. Lennox–Gastaut syndrome. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry 1993;93(2):96–9. (In Russ.)].2. Инструкция по медицинскому применению лекарственного препарата Иновелон®. [Guidelines for medical use of Inovelon®. (In Russ.)].Инструкция по медицинскому применению лекарственного препарата Иновелон®. [Guidelines for medical use of Inovelon®. (In Russ.)].3. Карлов В.А. Эпилепсия с преобладанием приступов падения. В кн.: Эпилепсия у детей и взрослых женщин и мужчин. Под ред. В.А. Карлова. М.: Медицина, 2010. С. 167–73. [Karlov V.А. Epilepsy with domination of drops’ attack. In: Epilepsy at children and adult women and men. V.А. Karlov (ed.). Мoscow: Меditsina, 2010. Pp. 167–73. (In Russ.)].Карлов В.А. Эпилепсия с преобладанием приступов падения. В кн.: Эпилепсия у детей и взрослых женщин и мужчин. Под ред. В.А. Карлова. М.: Медицина, 2010. С. 167–73. [Karlov V.А. Epilepsy with domination of drops’ attack. In: Epilepsy at children and adult women and men. V.А. Karlov (ed.). Мoscow: Меditsina, 2010. Pp. 167–73. (In Russ.)].4. Мухин К.Ю. Синдром Леннокса–Гасто. В кн.: Мухин К.Ю., Петрухин А.С., Холин А.А. Эпилептические энцефалопатии и схожие синдромы у детей. М.: Арт-Сервис Лтд, 2011. С. 176–224. [Мukhin K.Yu. Lennox–Gastaut syndrome. In: Мukhin K.Yu., Petrukhin А.S., Kholin A.А. Epileptic encephalopathies and similar syndromes in children. Мoscow: АrtService Ltd, 2011. Pp. 176–224. (In Russ.)].Мухин К.Ю. Синдром Леннокса–Гасто. В кн.: Мухин К.Ю., Петрухин А.С., Холин А.А. Эпилептические энцефалопатии и схожие синдромы у детей. М.: Арт-Сервис Лтд, 2011. С. 176–224. [Мukhin K.Yu. Lennox–Gastaut syndrome. In: Мukhin K.Yu., Petrukhin А.S., Kholin A.А. Epileptic encephalopathies and similar syndromes in children. Мoscow: АrtService Ltd, 2011. Pp. 176–224. (In Russ.)].5. Мухин К.Ю., Петрухин А.С., Калашникова Н.Б. Современные представления о детской эпилептической энцефалопатии с диффузными медленными пикволнами на ЭЭГ (синдром Леннокса–Гасто). М., 2002. 72 с. [Мukhin K.Yu., Petrukhin А.S., Kalashnikova N.B. Modern perceptions on the childhood epileptic encephalopathy with diffuse spike slow waves at EEG (Lennox–Gastaut syndrome). Мoscow, 2002. 72 p. (In Russ.)].Мухин К.Ю., Петрухин А.С., Калашникова Н.Б. Современные представления о детской эпилептической энцефалопатии с диффузными медленными пикволнами на ЭЭГ (синдром Леннокса–Гасто). М., 2002. 72 с. [Мukhin K.Yu., Petrukhin А.S., Kalashnikova N.B. Modern perceptions on the childhood epileptic encephalopathy with diffuse spike slow waves at EEG (Lennox–Gastaut syndrome). Мoscow, 2002. 72 p. (In Russ.)].6. Петрухин А.С. Синдром Леннокса–Гасто. В кн.: Мухин К.Ю., Петрухин А.С. Идиопатические формы эпилепсии: систематика, диагностика, терапия. М.: Арт-Бизнес-Центр, 2000. С. 158–75. [Petrukhin А.S. Lennox–Gastaut syndrome. In: Мukhin K.Yu., Petrukhin А.S. Idiopathic forms of epilepsy: systematic, diagnostics, therapy. Мoscow: Аrt-Business-Center, 2000. Pp. 158–75. (In Russ.)].Петрухин А.С. Синдром Леннокса–Гасто. В кн.: Мухин К.Ю., Петрухин А.С. Идиопатические формы эпилепсии: систематика, диагностика, терапия. М.: Арт-Бизнес-Центр, 2000. С. 158–75. [Petrukhin А.S. Lennox–Gastaut syndrome. In: Мukhin K.Yu., Petrukhin А.S. Idiopathic forms of epilepsy: systematic, diagnostics, therapy. Мoscow: Аrt-Business-Center, 2000. Pp. 158–75. (In Russ.)].7. Темин П.А., Никанорова М.Ю., Крапивкин А.И. и др. Синдром Леннокса–Гасто. В кн.: Темин П.А., Никанорова М.Ю. Диагностика и лечение эпилепсий у детей. М.: Можайск-Терра, 1997. С. 355–68. [Теmin P.А., Nikanorova М.Yu., Krapivkin А.I. et al. Lennox–Gastaut syndrome. In: Теmin P.А., Nikanorova М.Yu. Diagnostics and treatment of childhood epilepsies. Мoscow: Моzhaysk-Теrra, 1997. Pp. 355–68. (In Russ.)].Темин П.А., Никанорова М.Ю., Крапивкин А.И. и др. Синдром Леннокса–Гасто. В кн.: Темин П.А., Никанорова М.Ю. Диагностика и лечение эпилепсий у детей. М.: Можайск-Терра, 1997. С. 355–68. [Теmin P.А., Nikanorova М.Yu., Krapivkin А.I. et al. Lennox–Gastaut syndrome. In: Теmin P.А., Nikanorova М.Yu. Diagnostics and treatment of childhood epilepsies. Мoscow: Моzhaysk-Теrra, 1997. Pp. 355–68. (In Russ.)].8. Aicardi J., Levy Gomes A. The Lennox–Gastaut syndrome: clinical and electroencephalographic features. In: The Lennox–Gastaut syndrome. E. Niedermeyer, R. Degen (еds.). N.Y., 1988. Pр. 25–46.Aicardi J., Levy Gomes A. The Lennox–Gastaut syndrome: clinical and electroencephalographic features. In: The Lennox–Gastaut syndrome. E. Niedermeyer, R. Degen (еds.). N.Y., 1988. Pр. 25–46.9. Al-Banji M.H., Zahr D.K., Jan M.M. Lennox–Gastaut syndrome. Management update. Neurosciences (Riyadh) 2015;20(3):207–12.Al-Banji M.H., Zahr D.K., Jan M.M. Lennox–Gastaut syndrome. Management update. Neurosciences (Riyadh) 2015;20(3):207–12.10. Albini M., Morano A., Fanella M. et al. Effectiveness of rufinamide in the treatment of idiopathic generalized epilepsy with atypical evolution: case report and review of the literature. Clin EEG Neurosci 2014 Nov 23. [Epub ahead of print].Albini M., Morano A., Fanella M. et al. Effectiveness of rufinamide in the treatment of idiopathic generalized epilepsy with atypical evolution: case report and review of the literature. Clin EEG Neurosci 2014 Nov 23. [Epub ahead of print].11. Alsaad A.M., Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol 2014;78(6): 1264–71.Alsaad A.M., Koren G. Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials. Br J Clin Pharmacol 2014;78(6): 1264–71.12. Beaumanoir A., Dravet Ch. The Lennox–Gastaut syndrome. In: Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. J. Roger, M. Bureau, Ch. Dravet et al. (еds.) John Libbey, 1992. Pр. 307–12.Beaumanoir A., Dravet Ch. The Lennox–Gastaut syndrome. In: Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. J. Roger, M. Bureau, Ch. Dravet et al. (еds.) John Libbey, 1992. Pр. 307–12.13. Brodie M.J., Rosenfeld W.E., Vazquez B. et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899–909.Brodie M.J., Rosenfeld W.E., Vazquez B. et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899–909.14. Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90.Coppola G., Besag F., Cusmai R. et al. Current role of rufinamide in the treatment of childhood epilepsy: literature review and treatment guidelines. Eur J Paediatr Neurol 2014;18(6):685–90.15. Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat 2011;7:399–407.Coppola G. Update on rufinamide in childhood epilepsy. Neuropsychiatr Dis Treat 2011;7:399–407.16. Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70(21):1950–8.Glauser T., Kluger G., Sachdeo R. et al. Rufinamide for generalized seizures associated with Lennox–Gastaut syndrome. Neurology 2008;70(21):1950–8.17. Grosso S., Coppola G., Dontin S.D. et al. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies. Eur J Paediatr Neurol 2014;18(5):641–5.Grosso S., Coppola G., Dontin S.D. et al. Efficacy and safety of rufinamide in children under four years of age with drug-resistant epilepsies. Eur J Paediatr Neurol 2014;18(5):641–5.18. Guerrini R., Marini C. Epileptic еncephalopathies. In: Epilepsy and еpileptic seizures. S. Shorvon, R. Guerrini, M. Cook, S. Lhatoo (еds.). UK: Oxford University Press, 2013. Pр. 177–80.Guerrini R., Marini C. Epileptic еncephalopathies. In: Epilepsy and еpileptic seizures. S. Shorvon, R. Guerrini, M. Cook, S. Lhatoo (еds.). UK: Oxford University Press, 2013. Pр. 177–80.19. Hsieh D.T., Thiele E.A. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord 2013;6(3):189–98.Hsieh D.T., Thiele E.A. Efficacy and safety of rufinamide in pediatric epilepsy. Ther Adv Neurol Disord 2013;6(3):189–98.20. Kayani S., Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J Cent Nerv Syst Dis 2012;4:51–63.Kayani S., Sirsi D. The safety and tolerability of newer antiepileptic drugs in children and adolescents. J Cent Nerv Syst Dis 2012;4:51–63.21. Kessler S.K., McCarthy A., Cnaan A., Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox–Gastaut Syndrome. Epilepsy Res 2015;112:18–26.Kessler S.K., McCarthy A., Cnaan A., Dlugos D.J. Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox–Gastaut Syndrome. Epilepsy Res 2015;112:18–26.22. Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res 2012;2(2):33–7.Kim J.Y., Lee C.G., Yu H.J. et al. The efficacy and tolerability of rufinamide in intractable pediatric epilepsy. J Epilepsy Res 2012;2(2):33–7.23. Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010;122(3):202–8.Kluger G., Glauser T., Krauss G. et al. Adjunctive rufinamide in Lennox–Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010;122(3):202–8.24. Kluger G., Bauer B. Role of rufinamide in the management of Lennox–Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007;3:3–11.Kluger G., Bauer B. Role of rufinamide in the management of Lennox–Gastaut syndrome (childhood epileptic encephalopathy). Neuropsychiatr Dis Treat 2007;3:3–11.25. Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with Lennox–Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg 2013;115(7):926–9.Lee E.H., Yum M.S., Ko T.S. Effectiveness and tolerability of rufinamide in children and young adults with Lennox–Gastaut syndrome: a single center study in Korea. Clin Neurol Neurosurg 2013;115(7):926–9.26. Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox–Gastaut syndrome. Epilepsia 2014;55 Suppl 4:10–20.Montouris G.D., Wheless J.W., Glauser T.A. The efficacy and tolerability of pharmacologic treatment options for Lennox–Gastaut syndrome. Epilepsia 2014;55 Suppl 4:10–20.27. Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8.Mourand I., Crespel A., Gelisse P. Dramatic weight loss with rufinamide. Epilepsia 2013;54(1):e5–8.28. Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res 2014;108(9):1627–36.Ohtsuka Y., Yoshinaga H., Shirasaka Y. et al. Rufinamide as an adjunctive therapy for Lennox–Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan. Epilepsy Res 2014;108(9):1627–36.29. Palhagen S., Canger R., Henriksen O. et al. Rufinamide: a double-blind, placebocontrolled proof of principle trial in patients with epilepsy. Epilepsy Res 2001;43(2):115–24.Palhagen S., Canger R., Henriksen O. et al. Rufinamide: a double-blind, placebocontrolled proof of principle trial in patients with epilepsy. Epilepsy Res 2001;43(2):115–24.30. Thome-Souza S., Kadish N.E., Ramgopal S. et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia 2014;55(8): 1235–44.Thome-Souza S., Kadish N.E., Ramgopal S. et al. Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience. Epilepsia 2014;55(8): 1235–44.31. Verrotti A., Loiacono G., Ballone E. et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol 2011;44(5):347–9.Verrotti A., Loiacono G., Ballone E. et al. Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis. Pediatr Neurol 2011;44(5):347–9.32. Verrotti A., Loiacono G., Rossi A. et al. Successful treatment of refractory seizures with rufinamide in children with schizencephaly: report of 3 cases. J Child Neurol 2014;30(8):1079–83.Verrotti A., Loiacono G., Rossi A. et al. Successful treatment of refractory seizures with rufinamide in children with schizencephaly: report of 3 cases. J Child Neurol 2014;30(8):1079–83.33. Wheless J.W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24(12): 1520–5.Wheless J.W., Conry J., Krauss G. et al. Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of 7 clinical studies. J Child Neurol 2009;24(12): 1520–5.34. Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox–Gastaut syndrome: a comprehensive overview. Paediatric Drugs 2011;13(2):97–106.Wier H.A., Cerna A., So T.Y. Rufinamide for pediatric patients with Lennox–Gastaut syndrome: a comprehensive overview. Paediatric Drugs 2011;13(2):97–106.